Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists a Phase 2a study of elamipretide in patients undergoing renal artery angioplasty as terminated. The randomized, double-blind, placebo-controlled trial was designed to assess whether elamipretide reduced reperfusion injury; the excerpt provides no results or reason for termination.
- 01The single-center study enrolled patients with atherosclerotic renal artery stenosis undergoing angioplasty.
- 02Planned assessments included efficacy, pharmacokinetics, safety and tolerability.
- 03Termination is reported without an explanation or study outcomes.
Why it matters Editorial
The listing documents a terminated elamipretide trial but does not establish its efficacy or safety for reducing reperfusion injury.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide